ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2468

Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab

Paul Emery1, Hubert van Hoogstraten2, Shyamalie Jayawardena2, Erin K. Mangan3, Paula Cejas4 and Patrick Verschueren5, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2Sanofi Genzyme, Bridgewater, NJ, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Hospital Quirónsalud Infanta Luisa, Sevilla, Spain, 5Division of Rheumatology, University Hospital Leuven, Leuven, Belgium

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: ASCERTAIN (NCT01768572) was a 24-week, randomized, double-blind, double-dummy, parallel-group, 3-arm, safety study in patients with RA and inadequate response to or intolerance of TNF inhibitors receiving background conventional synthetic (cs)DMARDs. The purpose of this post hoc analysis was to examine outcomes for patients completing ASCERTAIN who were switched to sarilumab 200 mg every 2 weeks (q2w) subcutaneously (SC) in an open-label extension study (EXTEND, NCT01146652).

Methods: In ASCERTAIN, patients receiving background csDMARDs were randomized 1:1:2 to sarilumab 150 mg q2w SC, sarilumab 200 mg q2w SC, or tocilizumab every 4 weeks (q4w) intravenously (IV) starting at 4 mg/kg and increasing to 8 mg/kg if clinically indicated. Patients were eligible to enroll in EXTEND and receive open-label sarilumab 200 mg q2w after completing ASCERTAIN. Clinical endpoints were based on all available data as observed and were summarized through week 84 of EXTEND according to the original randomized treatment. Definitions used as cutoffs for remission and low disease activity (LDA) were DAS28-CRP <2.6 and <3.2 and clinical disease activity index (CDAI) ≤2.8 and ≤10.0, respectively. All patients who had not achieved individual parameters of remission, LDA, and ACR20/50/70 at enrollment into EXTEND were classified as nonresponders for that specific category.

Results: Of the 175 patients who completed ASCERTAIN, 93/96 from the tocilizumab group, 37/40 from the sarilumab 150 mg group, and 38/39 from the sarilumab 200 mg group entered EXTEND. Improvements observed in DAS28-CRP and CDAI in ASCERTAIN were maintained after the switch to open-label sarilumab in EXTEND through week 84 (data not shown). Regardless of initial treatment in ASCERTAIN, the proportions of patients who achieved ACR20/50/70 response, and DAS28-CRP and CDAI remission and LDA increased after switch to sarilumab 200 mg q2w in EXTEND (Table). The greatest increase in patients meeting definitions of remission and LDA was observed in patients initially receiving tocilizumab. Generally, a greater proportion of nonresponders who switched from sarilumab 150 mg q2w to 200 mg q2w achieved ACR20/50/70 response, and DAS28-CRP and CDAI remission and LDA compared with nonresponders who were maintained on 200 mg q2w. The most common treatment-emergent adverse events observed in the EXTEND safety population, which included all patients enrolled from ASCERTAIN and 4 other sarilumab studies, were infections and neutropenia.

Conclusion: Efficacy was maintained or improved in patients rolling over from ASCERTAIN into EXTEND. Increased efficacy was seen in all nonresponder categories, with the largest increases occurring in those who initially received tocilizumab. Although based on a limited population, these findings suggest that switching tocilizumab nonresponders to sarilumab may have favorable efficacy outcomes.



Disclosure: P. Emery, Abbott, AbbVie, Bristol-Myers Squibb, Pfizer, UCB, Merck Sharpe & Dohme, Roche, Novartis, Samsung, Takeda, Eli Lilly, Sanofi, and Regeneron Pharmaceuticals, Inc, 2,Abbott, AbbVie, Bristol-Myers Squibb, Pfizer, UCB, Merck Sharpe & Dohme, Roche, Novartis, Samsung, Takeda, Eli Lilly, Sanofi, and Regeneron Pharmaceuticals, Inc, 5; H. van Hoogstraten, Sanofi Genzyme, 3,Sanofi Genzyme, 1; S. Jayawardena, Sanofi Genzyme, 1,Sanofi Genzyme, 3; E. K. Mangan, Regeneron Pharmaceuticals, Inc., 1,Regeneron Pharmaceuticals, Inc., 3; P. Cejas, AbbVie, Bristol-Myers Squibb, Novartis, Pfizer, and Sun Pharma, 9; P. Verschueren, AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck Sharpe & Dohme, Pfizer, Roche, Sanofi, and UCB, 5,Pfizer chair for early RA management at KU Leuven, 6.

To cite this abstract in AMA style:

Emery P, van Hoogstraten H, Jayawardena S, Mangan EK, Cejas P, Verschueren P. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-sarilumab-in-patients-with-rheumatoid-arthritis-who-previously-received-sarilumab-or-tocilizumab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-sarilumab-in-patients-with-rheumatoid-arthritis-who-previously-received-sarilumab-or-tocilizumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology